National News
AtriCure to Announce Second Quarter 2020 Financial Results
07.07.2020
MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020 .AtriCure Announces Pricing of Public Offering of Common Stock
05.11.2020
MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price toAtriCure Announces Proposed Public Offering of Common Stock
05.11.2020
MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sellAtriCure Announces Results from CONVERGE IDE Clinical Trial
05.08.2020
Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure MASON, Ohio --(BUSINESS WIRE)--May 8, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting
04.30.2020
MASON, Ohio --(BUSINESS WIRE)--Apr. 30, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m.AtriCure Reports First Quarter 2020 Financial Results
04.29.2020
Worldwide revenue of $53.2 million – a decrease of 1.4% year over year U.S. revenue of $43.5 million – an increase of 1.1% year over year International revenue of $9.8 million – a decrease of 11.0% year over year MASON, Ohio --(BUSINESS WIRE)--Apr. 29, 2020-- AtriCure, Inc.AtriCure to Participate at Upcoming Investor Conferences
04.27.2020
MASON, Ohio --(BUSINESS WIRE)--Apr. 27, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences.AtriCure to Announce First Quarter 2020 Financial Results
04.15.2020
MASON, Ohio --(BUSINESS WIRE)--Apr. 15, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020 .AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting
04.13.2020
MASON, Ohio --(BUSINESS WIRE)--Apr. 13, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in theAtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update
04.09.2020
MASON, Ohio --(BUSINESS WIRE)--Apr. 9, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response toInternational News
AtriCure Completes Acquisition of SentreHEART
08.13.2019
MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
08.28.2018
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
06.05.2018
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
04.25.2017
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced itAtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
03.14.2017
MASON, Ohio --(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for theAtriCure Announces Approval for the cryoICE™ Platform in Japan
11.01.2016
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio --(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, todayAtriCure Receives CE Mark for the AtriClip® PRO2 Device
06.29.2016
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio --(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator inAtriCure Announces Approval for the AtriClip in Japan
01.19.2016
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio --(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA)In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
10.01.2013
AMSTERDAM, Netherlands --(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. ( Nasdaq: ATRC ), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training programPromising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
06.18.2013
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE --(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s